{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gary JM"],"funding":["Intramural NIH HHS","NCI","NCI NIH HHS","NIH","Center for Cancer Research"],"pagination":["2221-2232"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9574474"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(10)"],"pubmed_abstract":["PI3K/AKT/mTOR pathway hyperactivation is frequent in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). To model inhibition of mTOR, pre-T-cell lymphoblastic leukemia/lymphoma (pre-T LBL) tumor development was monitored in mice with T lymphocyte-specific, constitutively active AKT (Lck-MyrAkt2) that were either crossed to mTOR knockdown (KD) mice or treated with the mTOR inhibitor everolimus. Lck-MyrAkt2;mTOR KD mice lived significantly longer than Lck-MyrAkt2;mTOR wild-type (WT) mice, although both groups ultimately developed thymic pre-T LBL. An increase in survival was also observed when Lck-MyrAkt2;mTOR WT mice were treated for 8 weeks with everolimus. The transcriptional profiles of WT and KD thymic lymphomas were compared, and Ingenuity Pathway Upstream Regulator Analysis of d"],"journal":["Molecular cancer therapeutics"],"pubmed_title":["Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis."],"pmcid":["PMC9574474"],"funding_grant_id":["BC011065","ZIA BC011065","R01 CA77429","ZIA BC011064","R01 CA077429","ZIA BC010008","P30 CA006927","P30 CA06927","Z01 BC010008"],"pubmed_authors":["Chen JQ","Zhang K","Etienne M","Simpson RM","Thaiwong T","Kiupel M","Watson N","Zhang S","Kovalchuk AL","Xu J","Dubois W","Michalowski AM","Simmons JK","Peat TJ","Gamache BJ","Mock BA","Gary JM","Gaikwad S","Testa JR"],"additional_accession":[]},"is_claimable":false,"name":"Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis.","description":"PI3K/AKT/mTOR pathway hyperactivation is frequent in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). To model inhibition of mTOR, pre-T-cell lymphoblastic leukemia/lymphoma (pre-T LBL) tumor development was monitored in mice with T lymphocyte-specific, constitutively active AKT (Lck-MyrAkt2) that were either crossed to mTOR knockdown (KD) mice or treated with the mTOR inhibitor everolimus. Lck-MyrAkt2;mTOR KD mice lived significantly longer than Lck-MyrAkt2;mTOR wild-type (WT) mice, although both groups ultimately developed thymic pre-T LBL. An increase in survival was also observed when Lck-MyrAkt2;mTOR WT mice were treated for 8 weeks with everolimus. The transcriptional profiles of WT and KD thymic lymphomas were compared, and Ingenuity Pathway Upstream Regulator Analysis of d","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Oct","modification":"2026-05-27T19:09:30.959Z","creation":"2025-02-19T03:23:03.97Z"},"accession":"S-EPMC9574474","cross_references":{"pubmed":["32747423"],"doi":["10.1158/1535-7163.MCT-19-0671","10.1158/1535-7163.mct-19-0671"]}}